Main results
Eleven studies met the criteria for inclusion in this review, all were randomised clinical trials, two were double-blind. There were a total number of 1969 participants. The sequence generation was inadequate in one study, adequate in five studies and unclear in the remaining studies. The allocation of concealment was adequate in three studies and unclear in the remaining studies. Methadone appeared statistically significantly more effective than non-pharmacological approaches in retaining patients in treatment and in the suppression of heroin use as measured by self report and urine/hair analysis (6 RCTs, RR = 0.66 95% CI 0.56-0.78), but not statistically different in criminal activity (3 RCTs, RR=0.39; 95%CI: 0.12-1.25) or mortality (4 RCTs, RR=0.48; 95%CI: 0.10-2.39).
Authors' conclusions
Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy. It does not show a statistically significant superior effect on criminal activity or mortality.
P L A I N L A N G U A G E S U M M A R Y

Methadone maintenance therapy versus no opioid replacement therapy
Methadone maintenance treatment can keep people who are dependent on heroin in treatment programs and reduce their use of heroin. Methadone is the most widely used replacement for heroin in medically-supported maintenance or detoxification programs. Several non-drug detoxification and rehabilitation methods are also used to try and help people withdraw from heroin. However the review found that people have withdrawn from trials when they are assigned to a drug-free program. Consequently, there are no trials comparing methadone maintenance treatment with drug-free methods other than methadone placebo trials, or comparing methadone maintenance with methadone for detoxification only. These trials show that methadone can reduce the use of heroin in dependent people, and keep them in treatment programs.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Methadone maintenance treatment compared to No methadone maintenance treatment for opioid dependence 
How the intervention might work
The aspects of methadone that have led to its use as a substitute drug for heroin include the number of pharmacological features of opioids. At the basis of methadone maintenance treatment (MMT) is the observation that opioid analgesics can be substituted for one another (Jaffe 1990). Methadone at adequate doses (of 20mg to more than 100 mg) prevents or reverses withdrawal symptoms (Ward 1992), and thus reduces the need to use illegal heroin (Jaffe 1990). Methadone remains effective for approximately 24 hours, requiring a single daily dose rather than the more frequent administration of three to four times daily which occurs with the shorter-acting heroin (Jaffe 1990). Methadone can "block" the euphoric effects of heroin, discouraging illicit use and thereby relieving the user of the need or desire to seek heroin (Dole 1969) . This allows the opportunity to engage in normative activities, and "rehabilitation" if necessary. Methadone can cause death in overdosage, like other similar medications such as morphine, and for this reason it is a treatment which is dispensed under medical supervision and relatively strict rules. In summary, methadone is a long-acting opioid analgesic with well-understood pharmacological characteristics which make it suitable for stabilising opioid dependent patients in a maintenance treatment approach. There is evidence that the quality of the therapeutic relationship with staff in methadone clinics plus the intensity of these ancillary services, combined with the dose of methadone prescribed will all act to enhance the outcome for methadone treatment (Ward 1992), although this is not the focus of this review. 
Why it is important to do this review
O B J E C T I V E S
The present systematic review aimed to provide an evaluation of the effectiveness of methadone maintenance treatment on opioid dependence compared with treatments that did not include an opioid replacement therapy. The focus of the review is on retention in treatment, opioid use as measured by objective urine results and from self-report, as well as criminal activity and patient mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
The literature was reviewed for all clinical controlled trials of MMT against another treatment which does not use opioid replacement therapy.
Types of participants
Individuals who were opioid dependent were the target population for this review. No distinction was made between those using heroin and those who have been in methadone treatment prior to entering the research trial treatment. No restrictions were imposed in terms of studies of outpatients, inpatients, those with comorbid states, etc.
Types of interventions
Interventions were included if they used methadone maintenance therapy (MMT). The MMT interventions were included even where they also employed other treatments, such as behavioural therapies or outpatient rehabilitation. The control groups were treated with placebo medication, withdrawal or detoxification (with or without ancillary medication), drug-free rehabilitation treatment (such as therapeutic communities), and no treatment or wait-list controls. • "Australian Bibliographic Network (ABN).
Types of outcome measures
All searches included non-English language literature and studies with English abstracts were assessed for inclusion. When considered likely to meet inclusion criteria, studies were translated.
Data collection and analysis
Selection of studies
Each potentially relevant study located in the search was obtained and independently assessed for inclusion by two of three reviewers. Data extraction for each study was undertaken by the same two reviewers, again independently.
Data extraction and management
Each potentially relevant study located in the search was obtained and independently assessed for inclusion by two of three reviewers. Data extraction for each study was undertaken by the same two reviewers, again independently. A standardised checklist was used for data extraction. Disagreement was dealt with by the third reviewer, acting as a mediator. If unresolved disagreements on inclusion, study quality or extraction occurred they were referred to the editor.
Assessment of risk of bias in included studies
Due the type of comparisons analysed (MMT versus methadone detoxification or waiting list), blinding is often difficult to apply. As such, methodological quality was assessed by assessment of the randomisation procedure and the likelihood that randomisation was not biased: A. Low risk of bias (allocation clearly independent of clinical staff ); B. Moderate risk of bias (some doubt about the independence of the allocation procedure); and C. High risk of bias (inadequate separation of randomisation from clinical staff ).
Measures of treatment effect
A standardised effect size was calculated for each study, based on the main outcome measure reported. Where possible (relative risks and 95% confidence intervals for dichotomous outcomes (retention) using a random effects model and standardised mean differences for continuous outcomes were presented. To assess for statistical heterogeneity a test of homogeneity was undertaken. A pooled effect size estimate was derived for each domain of measurement (retention in treatment, urine analysis results for heroin/ morphine ), self-reported heroin use, and criminal activity. The retention in treatment and urine results were reported as the number of patients retained or the number with a morphine-positive urine result at follow-up, a form of reporting that allowed for dichotomous analysis of those data.
Data synthesis
The results were integrated from the meta-analytic review into a discussion taking into consideration other publications including large-scale observational studies, studies of the pharmacology of methadone, and studies of the effect of MMT on HIV seroconversion. Convergence of the evidence from the meta-analysis and the narrative review was taken to indicate a robust conclusion.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
We considered fourteen studies for inclusion, three were excluded because they did not satisfy the inclusion criteria (see Characteristics of excluded studies table) and eleven were included (Characteristics of included studies Charachteristics table) with a total of 1969 participants.
Included studies
Eleven studies were included in this review. Refer to Characteristics of included studies Table for more detailed information.
Treatment regimes and settings
The first study by Dole (Dole 1969) was a two group randomised trial where patients either received methadone or placed on a waitlist. The study by Gunne (Gunne 1981) randomly allocated patients to receive methadone maintenance or to be allocated to a drug-free rehabilitation. None of the patients allocated to drugfree rehabilitation took up the offer, refusing treatment after they had learnt that they would not receive methadone. There were two placebo controlled trials (Newman 1979, Strain 1993a). As such, the results from the studies appear to use moderate to high doses on average.
Duration of the trials
As shown in the table of included studies, the interventions generally lasted for significant time of several weeks up to two years, although one study only ran 45 days (Vanichseni 1991).
Countries in which the studies were conducted
The studies were conducted in a range of countries including; USA 
Participants
The participants (N=1969) were largely typical of heroin dependant individuals, in terms of age and gender characteristics. In some studies, only males were included but where females were included the gender distribution was as one would expect, with majority of the participants being male. They tended to be approximately 30 to 40 years of age, often unemployed and unmarried, with previous treatment histories and prevalence of use of other drugs, consistent with what is known about heroin users presenting for treatment.
Types of comparisons
The review compared methadone maintenance treatment with no methadone maintenance treatment. All studies were assessed to determine whether they provided data on retention in treatment, codeable results from urine/hair analysis, self-reported drug use (particularly heroin use), criminal activity and mortality. After reviewing the studies, it was realised that it was not possible to include urine/hair results for cocaine and benzodiazepines as these were not reported in an analysable form for most studies. It was not possible to analyse data on either cocaine or benzodiazepine positive urines from these studies. However, it was possible to code data on retention in treatment, morphine positive urine or hair analysis, self-reported heroin use, criminal activity and mortality.
Excluded studies
Three studies were not included. Refer to the Characteristics of excluded studies for the reason for exclusion. 
Risk of bias in included studies
Blinding
Of the eleven studies included in this review, two were placebocontrolled trials (Newman 1979, Strain 1993a). Both of these studies were double-blind but Strain 1993a did not provide sufficient data to be confident about the concealment of allocation. The remaining studies were not blinded.
Incomplete outcome data
All studies addressed the issue of incomplete outcome data adequately and were independently deemed by reviewers to be free of other major bias ( Figure 1; Figure 2 ). 
Effects of interventions
D I S C U S S I O N
Summary of main results
The results of the meta-analysis indicate that methadone is able to retain patients in treatment better than the drug-free alternatives (placebo medication, offer of drug-free treatment, detoxification, or wait-list control), to suppress heroin use based on morphine (the heroin metabolite) found in urine/hair samples, and patient self-report. There was a greater reduction in criminal activity and mortality among the MMT patients, but these differences were not statistically significant. 
Overall completeness and applicability of evidence
Interestingly, the results from these eleven randomised trials all showed statistically significant positive benefits from methadone treatment, despite their small sample sizes. Additional support for the efficacy of methadone maintenance treatment comes from the results of many observational studies wherein some statistical form of control has addressed alternative explanations of apparent effectiveness. These large scale observational studies have generally supported the results from the randomised clinical trials in showing that methadone maintenance treatment reduces the use of heroin and decreases criminal activity (Ward 1998). As noted earlier there is a broader international literature showing advantages for methadone beyond other treatments in terms of reduction of death (Ward 1998), even though the randomised trial data do not show this result.
Another relevant outcome to be considered would be seroconversion for HIV, which is the object of a separate Cochrane review (Gowing 2004). Methadone maintenance treatment has been shown to reduce HIV risk taking behaviour (specifically reduction in needle sharing) and thereby has achieved a reduction in the transmission of HIV. Consistent with this it has been shown that methadone maintenance treatment is protective of patients, reducing HIV infection in geographic locations where HIV had spread rapidly among injecting drug users who had not entered treatment. We have commented elsewhere on two large prospective cohort studies in the USA which found methadone maintenance treatment protected against HIV infection (Ward 1998). This outcome could not be addressed here as there are no randomised trials of methadone that have included HIV status as a measure, the evidence coming from observational studies.
Quality of the evidence
It is notable that the doses of methadone used in the randomised clinical trials are probably slightly higher than are being used currently in routine clinical practice in some parts of the world. This relative underdosing in clinical practice may lead to a reduction in the effectiveness of methadone, as the response to methadone treatment is dose-dependent. In addition, it is important to recognise that methadone treatment in these trials was often provided with substantial ancillary services. These ancillary services have included counselling, psycho-social services, medical services and often psychiatric care. The quality of the therapeutic relationship with staff in methadone clinics plus the intensity of these ancillary services, combined with the dose of methadone prescribed will all act to enhance the outcome for methadone treatment. The extent that clinical programs move away from such an approach might be expected to impact on the effectiveness of methadone. This does not imply that methadone maintenance treatment will become ineffective. Even allowing for some reduction in effectiveness when methadone is not provided in the fashion that it has been in the clinical trials, it is still likely to be effective. The effects of methadone may be modest, if they are judged by unrealistic expectations of patients can easily achieve enduring abstinence from opioid drugs. Methadone nonetheless attracts and retains more patients than alternative treatments, and it does produce better outcomes amongst those who complete treatment. Methadone maintenance appears to provide better outcomes than simple detoxification programs, where the evidence suggests that shortterm detoxification has no enduring effect on drug use (Mattick 1996).
A U T H O R S ' C O N C L U S I O N S Implications for practice
The implications of the results of the meta-analytic review conducted and reported herein for clinical practice are that methadone maintenance treatment is an effective intervention for the management of heroin dependence. Methadone retains patients in treatment and reduces heroin use. Methadone should be supported as a maintenance treatment for heroin dependence.
Implications for research
Overall there are a relatively limited number of randomised clinical trials on the efficacy of methadone treatment compared to placebo. It does not seem feasible at this stage to conduct further randomised trials of methadone treatment. However, evidence on reduction of criminal activity and mortality from clinical trials is lacking calling for an additional systematic review of observational studies. Moreover, monitoring of the outcome of standard methadone treatment in clinical practice may be important as a research activity to demonstrate its ongoing effectiveness, or to determine whether its effectiveness is being compromised through the reduction of ancillary services or reduction in adequate dose levels.
A number of measures (e.g., of other drug use, physical health, and psychological health) were too infrequently and irregularly reported in the literature to be usefully integrated in the quantitative review, but future research might address these important areas.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Dolan 2003
Methods
Gunne 1981
Methods Two group randomised clinical trial. Randomisation: after eligibility established subjects were randomly allocated to methadone maintenance or to drug-free treatment. 
Newman 1979
Methods Double blind randomised clinical trial Randomisation: subjects randomly allocated on discharge from hospital after 2 week stabilisation on 60mg methadone to detoxification or continued maintenance Participants Geographic region: Hong Kong Study setting: Hospital and outpatient clinic n = 100 males mean age = 38 years Eligibility criteria: male, 22-58 years, history of heroin dependence for at least 4 years and at least one previous treatment, current heroin dependence by three consecutive positive urine samples, voluntary application for admission (criminal justice referrals excluded), resident with fixed address, absence of past or present major psychiatric or medical illness 
